Description |
Thi-DPPY (compound 8e) is a potent and orally active JAK3 inhibitor with IC50 values of 62.4, 1.38 nM for BTK, JAK, respectively. Thi-DPPY shows anti-proliferative activity against HBE cells. Thi-DPPY shows anti-inflammatory activity in vivo. Thi-DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF)[1].
|
Related Catalog |
|
Target |
JAK3:1.38 nM (IC50)
BTK:62.4 nM (IC50)
|
In Vitro |
DPPY (compound 8e) shows anti-proliferative activity against HBE (human bronchial epithelia) cells with an IC50 of 39.0 µM[1].
|
In Vivo |
DPPY (30, 60 mg/kg; i.g., once daily for 14 days) shows anti-IPF agents on the lung morphology and lung coefficient in mouse model[1]. DPPY (30, 60 mg/kg) significantly decreases the expression of IL-6, IL-17A, TNF-α and MDA in lung tissue in a dose dependent manner[1]. Animal Model: 5-6 week old, 20-25 g, C57BL mice (BLM-induced pulmonary inflammation and pulmonary fibrosis model)[1] Dosage: 30, 60 mg/kg Administration: I.g.; once daily for 14 days Result: Attenuated the pulmonary morphology changes and reduced the collagen disposition induced by BLM in mouse lung.
|
References |
[1]. Zhu Y, et al. Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis. Bioorg Med Chem. 2020 Jan 15;28(2):115254.
|